CXCR4 and breast carcinoma: It was recently suggested that knockdown of CXCR4 (with RNA interference or pharmacological inhibition with AMD3100) substantially limited orthotopic growth of breast cancer cells in vivo and prevented the development of macroscopically detectable metastases [30].